EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

NCT05458401 · clinicaltrials.gov ↗

COMPLETED

Status

256

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Trastuzumab deruxtecan

Sponsor

Daiichi Sankyo